Sign in

    Chloe

    Research Analyst at Scotiabank

    No publicly available information could be found to confirm a Chloe working as an analyst at Scotiabank, including details on job title, coverage universe, performance track record, career timeline, or professional credentials. There is no verified LinkedIn profile or press coverage matching these specifics. As such, a comprehensive profile cannot be provided at this time.

    Chloe's questions to Syndax Pharmaceuticals (SNDX) leadership

    Chloe's questions to Syndax Pharmaceuticals (SNDX) leadership • Q2 2025

    Question

    Chloe, on for George Farmer, asked about real-world cardiac safety monitoring for Revuforge, how to model the Royalty Pharma interest expense, and the market opportunity and positioning for Nyktymbo in idiopathic pulmonary fibrosis (IPF).

    Answer

    CMO Dr. Nick Botwood assured that QT prolongation is managed well with label guidelines and no new safety concerns have emerged commercially. CFO Keith Goldan explained the royalty expense is 13.8% of Nyktymbo net sales. CEO Michael Metzger described IPF as a large market with high unmet need where Nyktymbo's novel mechanism could be highly impactful, with Phase 2 data expected next year.

    Ask Fintool Equity Research AI